Is Enovis Corporation (ENOV) a Buy, Sell, or Hold?
Enovis Corporation
NYSE:ENOV
$25.59 USD
$0.94 (3.81%)
- Volume
- 993.97K
- Average Volume
- 1.19M
- Market Capitalization
- $1.47B
- P/E Ratio
- -1.28
- Dividend Yield
- 0.00%
- Price Target
- $32.00
- Year High
- $34.28
- Year Low
- $19.14
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.04
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Damien McDonald |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Current Symbol | ENOV |
| CUSIP | 194014502 |
| CIK | 0001420800 |
| Web | https://www.enovis.com |
| Phone | 302 252 9190 |
| Currency | USD |
| Employees | 7802 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.96 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.04 |
| Quick Ratio | 1.05 |
| Cash Ratio | 0.05 |
Sales & Book Value
| Annual Sales | $2.25B |
| Price / Sales | 0.65 |
| Cash Flow | 0.63 |
| Price / Cash Flow | 41.01 |
| Price / Book | 0.98 |
Price Target and Rating
| Average Stock Price Forecast | $32.00 |
| High Stock Price Forecast | $52.00 |
| Low Stock Price Forecast | $29.00 |
| Forecast Upside/Downside | -20.03% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 13 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-20.86 |
| Trailing P/E Ratio | -1.28 |
| PEG Ratio | 0.02 |
| P/E Growth | 0.02 |
| Net Income | $-1.18B |
| Net Margin | -49.91% |
| Pretax Margin | -48.34% |
| Return on Equity | -60.13% |
| Return on Assets | -29.68% |
Financials Score
| AltmanZ Score | -0.26 |
| Piotroski Score | 4.00 |
| Working Capital | 631.02M |
| Total Assets | 3.83B |
| Ebit | -1.04B |
| Market Cap | 1.51B |
| Total Liabilities | 2.35B |
Poll Results
About Enovis Corporation (NYSE:ENOV) Stock
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulat ... ors for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
2026-07-13 08:30:00
DALLAS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, today announced the U.S. launch of CT-RevitL™, the next-generation veterinary PBM laser therapy system from its Companion Animal Health business. CT-RevitL delivers enhanced clinical performance, greater mobility and a more intuitive treatment experience for veterinary teams and their patients.
4 Top Growth Stocks Worth Buying Under $100 Today
2026-07-03 08:30:00
These four under-the-radar stocks are built to benefit from powerful secular trends that could reward patient, long-term investors.
2026-06-08 08:30:00
The DonJoy Spinamic® Hybrid Scoliosis Brace is a first-of-its-kind device that integrates rigid corrective elements into a breathable, adjustable design to improve both clinical outcomes and patient compliance in adolescent idiopathic scoliosis The DonJoy Spinamic® Hybrid Scoliosis Brace is a first-of-its-kind device that integrates rigid corrective elements into a breathable, adjustable design to improve both clinical outcomes and patient compliance in adolescent idiopathic scoliosis
ront Street Bought 384K More Shares of Enovis in Q1. Is ENOV a Buy Now?
2026-05-22 20:08:46
Enovis develops orthopedic and rehabilitation devices for healthcare providers, serving a broad spectrum of musculoskeletal patient needs.
Does Enovis (ENOV) Have the Potential to Rally 65.45% as Wall Street Analysts Expect?
2026-05-13 10:55:28
The average of price targets set by Wall Street analysts indicates a potential upside of 65.5% in Enovis (ENOV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Enovis Q1 Earnings Call Highlights
2026-05-10 04:07:33
Enovis NYSE: ENOV reported a solid start to 2026, with management pointing to share gains in its reconstructive surgery business, stable growth in prevention and recovery, and continued investment in new products including ARVIS and Nebula.
Enovis Corporation (ENOV) Q1 2026 Earnings Call Transcript
2026-05-07 15:11:27
Enovis Corporation (ENOV) Q1 2026 Earnings Call Transcript
Enovis (ENOV) Q1 Earnings and Revenues Beat Estimates
2026-05-07 08:46:25
Enovis (ENOV) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $0.81 per share a year ago.
Frequently Asked Questions
-
What is the current Enovis Corporation (ENOV) stock price?
-
Enovis Corporation(NYSE:ENOV) stock price is $25.59 in the last trading session. During the trading session, ENOV stock reached the peak price of $34.28 while $19.14 was the lowest point it dropped to. The percentage change in ENOV stock occurred in the recent session was 3.81% while the dollar amount for the price change in ENOV stock was $0.94.
-
ENOV's industry and sector of operation?
-
The NYSE listed ENOV is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of ENOV?
-
Patricia A. Lang | Advisor
Oliver Engert | Chief Administrative Officer
John Kleckner | Vice President, Controller & Chief Accounting Officer
Kyle William Rose | Vice President of Investor Relations
Louie Vogt | Group President of Reconstructive -
How many employees does ENOV have?
-
Number of ENOV employees currently stands at 7802. ENOV operates from 2711 Centerville Road, Wilmington, DE 19808, US.
-
Link for ENOV official website?
-
Official Website of ENOV is: https://www.enovis.com
-
How do I contact ENOV?
-
ENOV could be contacted at phone #302 252 9190 and can also be accessed through its website. ENOV operates from 2711 Centerville Road, Wilmington, DE 19808, US.
-
How many shares of ENOV are traded daily?
-
The average number of ENOV shares traded daily for last 3 months was 1.19M.
-
What is the market cap of ENOV currently?
-
The market value of ENOV currently stands at $1.47B with its latest stock price at $25.59